This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Merck (MRK) Keytruda Betters Survival in Adjuvant Lung Cancer
by Zacks Equity Research
Merck's (MRK) phase III study evaluating Keytruda for adjuvant stage IB-IIIA non-small cell lung cancer (NSCLC) meets one of its dual primary endpoints of disease-free survival (DFS).
Pfizer (PFE) Partners Beam Therapeutics for Rare Disease Drugs
by Zacks Equity Research
Pfizer (PFE) collaborates with Beam Therapeutics (BEAM) to advance the next generation of gene-editing therapies.
Moderna (MRNA) Up on Plans to Get Omicron Booster Ready in 2022
by Zacks Equity Research
Moderna (MRNA) plans to begin clinical development of its Omicron-specific variant vaccine early in 2022 and expects to make it available for the public in the fall of 2022.
Sarepta's (SRPT) DMD Gene Therapy Study Data Fails to Impress
by Zacks Equity Research
Sarepta's (SRPT) DMD gene therapy candidate achieves statistically significant improvement in patients but the data fails to meet market expectations. Stock down.
Best Growth Stocks to Buy for January 11th
by Zacks Equity Research
AN, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 11, 2022
Omicron Vaccines to Hit Market Soon? ETF Areas to Benefit
by Sanghamitra Saha
Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.
Zacks.com featured highlights include: TotalEnergies SE, Nutrien, FedEx Corp. and Pfizer Inc.
by Zacks Equity Research
TotalEnergies SE, Nutrien, FedEx Corp. and Pfizer Inc. are included in this screen of the week article.
Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View (Revised)
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.
Why the Earnings Surprise Streak Could Continue for Pfizer (PFE)
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.
AstraZeneca (AZN) Inks Deal to Develop ATTR-CM Candidate
by Zacks Equity Research
AstraZeneca (AZN) inks collaboration and license agreement with Neurimmune AG to develop/commercialize the latter's NI006 for treating transthyretin amyloid cardiomyopathy.
Sanofi (SNY) Inks Deal to Develop AI-Driven Precision Medicines
by Zacks Equity Research
Sanofi (SNY) signs a collaboration agreement with Exscientia to develop precision-engineered medicines in oncology and immunology using the latter's AI-driven platform.
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, Eli Lilly and J&J
by Zacks Equity Research
Pfizer, AbbVie, Eli Lilly and J&J are included in this analyst blog.
4 Lucrative Bets Boasting High Earnings Yield
by Rimmi Singhi
TotalEnergies SE (TTE), Nutrien (NTR), FedEx (FDX) and Pfizer (PFE) could be some attractive bets if you are looking for high earnings yield picks.
AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS
by Zacks Equity Research
AbbVie's (ABBV) application seeking approval of Rinvoq for nr-axSpA was based on data from the phase III SELECT-AXIS 2 (Study 2) study.
Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies
by Zacks Equity Research
Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.
Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt
by Zacks Equity Research
Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.
Exelixis (EXEL) Amends Agreement With Iconic Therapeutics
by Zacks Equity Research
Exelixis (EXEL) gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic.
Lilly (LLY) Inks Deal for Multiple Neurologic Indications
by Zacks Equity Research
Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.
Pharma Stock Roundup: FDA Nod to PFE Booster for Age 12-15, Breakthrough Tag to ABBV Drug
by Kinjel Shah
FDA authorizes Pfizer's (PFE) booster shot for adolescents 12 -15 years of age and grants Breakthrough Therapy tag to AbbVie's (ABBV) lung cancer candidate.
Zacks Investment Ideas feature highlights: AbbVie, Inc. and Pfizer Inc
by Zacks Equity Research
AbbVie, Inc. and Pfizer Inc are highlighted in this investment idea article.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $54.84, marking a -1.42% move from the previous day.
Moderna (MRNA) Begins Dosing in Study on Vaccine Against EBV
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase I study evaluating its Epstein-Barr virus vaccine candidate, mRNA-1189.
How to Select Stocks During Volatile Market Periods
by Bryan Hayes
How to Select Stocks During Volatile Market Periods
4 Reasons Why You Should Add AbbVie (ABBV) to Your Portfolio
by Zacks Equity Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.